Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and agingLinda S. Steelman, James A. McCubrey, William H. Chappell et al.|Aging|2011Cited by 707
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human HealthWilliam H. Chappell, James A. McCubrey, Massimo Libra et al.|Oncotarget|2011Cited by 579
Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapyLinda S. Steelman, James A. McCubrey, Richard A. Franklin et al.|Leukemia|2011Cited by 263
PIK3CA mutations in human solid tumors: Role in sensitivity to various therapeutic approachesGiovanni Ligresti, Massimo Libra, Loredana Militello et al.|Cell Cycle|2009Cited by 213
Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathwayAlberto M. Martelli, James A. McCubrey, Camilla Evangelisti et al.|Leukemia|2011Cited by 206